2018
Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD. Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment. Gynecologic Oncology Reports 2018, 25: 41-44. PMID: 29946554, PMCID: PMC6014583, DOI: 10.1016/j.gore.2018.05.011.Peer-Reviewed Original ResearchLow-grade serous ovarian carcinomaTreatment optionsHormonal treatmentRecurrent low-grade serous ovarian cancerRecurrent low-grade serous ovarian carcinomaLow-grade serous ovarian cancerDramatic clinical responseDrug-related toxicityEffective treatment optionNew treatment optionsSerial CT scansSerous ovarian cancerSerous ovarian carcinomaMitogen-activated protein kinase inhibitorOral steroidsRECIST 1.1Clinical responseMultiple chemotherapyOvarian carcinomaTarget lesionsOvarian cancerCT scanResponse durationBinimetinibKRAS G12
2010
Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma
Lipstein M, O'Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-Induced Tumor Lysis Syndrome in a Patient With HIV-Negative Plasmablastic Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2010, 10: e43-e46. PMID: 21856550, DOI: 10.3816/clml.2010.n.074.Peer-Reviewed Original ResearchConceptsTumor lysis syndromePlasmablastic lymphomaLysis syndromeHIV-negative plasmablastic lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaBortezomib-based treatmentHIV-negative patientsDramatic clinical responseB-cell lymphomaWorld Health OrganizationClinical responseImmunocompetent patientsAggressive lymphomaRare lymphomaMultiple myelomaOptimal treatmentLymphomaPatientsHealth OrganizationSyndromeStandard recommendationsTreatmentMyelomaSubtypes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply